Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Effect of albumin on human liver microsomal and recombinant CYP1A2 activities: impact on in vitro-in vivo extrapolation of drug clearance.

Wattanachai N, Tassaneeyakul W, Rowland A, Elliot DJ, Bowalgaha K, Knights KM, Miners JO.

Drug Metab Dispos. 2012 May;40(5):982-9. doi: 10.1124/dmd.111.044057. Epub 2012 Feb 13.

PMID:
22331994
2.

Characterization of niflumic acid as a selective inhibitor of human liver microsomal UDP-glucuronosyltransferase 1A9: application to the reaction phenotyping of acetaminophen glucuronidation.

Miners JO, Bowalgaha K, Elliot DJ, Baranczewski P, Knights KM.

Drug Metab Dispos. 2011 Apr;39(4):644-52. doi: 10.1124/dmd.110.037036. Epub 2011 Jan 18.

PMID:
21245288
3.

Spironolactone and canrenone inhibit UGT2B7-catalyzed human liver and kidney microsomal aldosterone 18beta-glucuronidation: a potential drug interaction.

Knights KM, Bowalgaha K, Miners JO.

Drug Metab Dispos. 2010 Jul;38(7):1011-4. doi: 10.1124/dmd.110.032870. Epub 2010 Mar 19.

PMID:
20304966
4.

Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: inhibition by NSAIDs.

Knights KM, Winner LK, Elliot DJ, Bowalgaha K, Miners JO.

Br J Clin Pharmacol. 2009 Sep;68(3):402-12. doi: 10.1111/j.1365-2125.2009.03469.x.

5.

Influence of N-terminal domain histidine and proline residues on the substrate selectivities of human UDP-glucuronosyltransferase 1A1, 1A6, 1A9, 2B7, and 2B10.

Kerdpin O, Mackenzie PI, Bowalgaha K, Finel M, Miners JO.

Drug Metab Dispos. 2009 Sep;37(9):1948-55. doi: 10.1124/dmd.109.028225. Epub 2009 Jun 1.

PMID:
19487247
6.
7.
8.

The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes.

Bowalgaha K, Miners JO.

Br J Clin Pharmacol. 2001 Nov;52(5):605-9.

Supplemental Content

Loading ...
Support Center